Flutamide
- Generic Name
- Flutamide
- Brand Names
- Eulexin
- Drug Type
- Small Molecule
- Chemical Formula
- C11H11F3N2O3
- CAS Number
- 13311-84-7
- Unique Ingredient Identifier
- 76W6J0943E
- Background
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
- Indication
For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
- Associated Conditions
- Stage B2-C metastatic Carcinoma of the Prostate, Stage D2 metastatic Carcinoma of the Prostate
- Associated Therapies
- -
Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Ente Ospedaliero Ospedali Galliera
- Target Recruit Count
- 125
- Registration Number
- NCT06601205
- Locations
- 🇮🇹
Medical Oncology Ente Ospedaliero Ospedali Galliera, Genova, Italy
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2050
- Registration Number
- NCT05050084
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 10
- Registration Number
- NCT04597099
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2478
- Registration Number
- NCT04513717
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Wonju Severance Christian Hospital
- Target Recruit Count
- 164
- Registration Number
- NCT04248621
- Locations
- 🇰🇷
Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of
🇰🇷Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of
🇰🇷Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Conditions
- Interventions
- Drug: AbirateroneDrug: BicalutamideDrug: DegarelixDrug: FlutamideDrug: DocetaxelDrug: Goserelin AcetateDrug: Histrelin AcetateDrug: Leuprolide AcetateDrug: NilutamideProcedure: OrchiectomyOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: PrednisoneProcedure: Radical ProstatectomyDrug: Triptorelin
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1273
- Registration Number
- NCT03678025
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
- Conditions
- Interventions
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2024-11-22
- Target Recruit Count
- 24
- Registration Number
- NCT03507608
- Locations
- 🇺🇸
SKCCC at Johns Hopkins, Baltimore, Maryland, United States
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 612
- Registration Number
- NCT03070886
- Locations
- 🇺🇸
Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸MyMichigan Medical Center Saginaw, Saginaw, Michigan, United States
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 206
- Registration Number
- NCT02918968
- Locations
- 🇯🇵
Site JP00051, Iizuka, Fukuoka, Japan
🇯🇵Site JP00019, Sagamihara, Kanagawa, Japan
🇯🇵Site JP00024, Nagoya, Aichi, Japan
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT02742675
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.